Adenomatous polyps typically do not cause symptoms unless they progress to colon cancer. Even then, there may be no sign of a problem until the malignancy is advanced. This is why colon cancer ...

Frequent colorectal polyp diagnoses in first- and second-degree relatives are associated with an increased risk for colorectal cancer (CRC), especially early-onset CRC. Researchers evaluated the ...

The frequency of polyp diagnoses in close relatives was strongly associated with colorectal cancer risk. Polyp history in second-degree relatives was only influential with multiple polyp diagnoses.

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.29 billion and currently ...

(Jan. 20, 2025) The incidence of colon cancer in younger adults is rapidly increasing and doctors at Nantucket Cottage Hospital are stressing the importance of regular screenings. There has been a 51 ...

Forcing a struggling child to take any medicine can lead to vomiting or choking. Using a better technique can sometimes get rid of the child's resistance. Doctors can sometimes replace a bad-tasting ...

Dr. Allison Hoppe’s eyes were glued to the computer screen Monday as she carefully maneuvered a controller and scanned for ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...

GSK plc (LSE/NYSE: GSK) today announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, ...

Today on the Medscape Medical Minute: Researchers find subtle signs of neurodegeneration decades before the start of motor symptoms in Huntington’s disease; colorectal polyps in first- and ...

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...